Article
The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Jan 2006
Spurdle Amanda B, Antoniou Antonis C, Kelemen Livia, Holland Helene, Peock Susan, Cook Margaret R, Smith Paula L, Greene Mark H, Simard Jacques, Plourde Marie, Southey Melissa C, Godwin Andrew K, Beck Jeanne, Miron Alexander, Daly Mary B, Santella Regina M, Hopper John L, John Esther M, Andrulis Irene L, Durocher Francine, Struewing Jeffery P, Easton Douglas F, Chenevix-Trench Georgia
Abstract excerpt
This is by far the largest study of its kind to date, and further suggests that AIB1 does not play a substantial role in modifying the phenotype of BRCA1 and BRCA2 carriers. The AIB1 gene encodes the AIB1/SRC-3 steroid hormone receptor coactivator, and amplification of the gene and/or protein occurs in breast and ovarian tumors. A CAG/CAA repeat length polymorphism encodes a stretch of 17 to 29 glutamines in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.